Author

Mei Xue

Institution: BeOne Medicines (Switzerland)

Observed institution: BeOne Medicines (Switzerland)

ORCID: 0009-0008-8087-1143

Observed ORCID: 0009-0008-8087-1143

OpenAlex ID: A5122939784

Prospective patient preference study for Bruton tyrosine kinase inhibitor (BTKi) treatment attributes and factors affecting patient shared decision-making in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in the United States (US)

2026 · Sikander Ailawadhi, Swetha Challagulla, et al. · Expert Review of Hematology · 3

Patient medication preferences in follicular lymphoma in the United States: a discrete choice experiment

2026 · Sameh Gaballa, Mei Xue, et al. · Postgraduate Medicine · 2

Real-world treatment switching and sequencing to next line of therapy of zanubrutinib, acalabrutinib, and ibrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma

2026 · Javier Pinilla-Ibarz, Mei Xue, et al. · Expert Review of Hematology

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia

2026 · Mazyar Shadman, Asher Chanan-Khan, et al. · Future Oncology

Works count: 4

Citation count: 5

H-index: 2

I10-index: